Pharmaceuticals company Alembic Pharmaceuticals announced Q1FY25 results: Financial Highlights: Net Sales increased 5% to Rs 1,562 crore. Net Profit up 12% to Rs 135 crore. EBITDA up 14% to Rs 239 crore. Operational Highlights: India Branded Business grew 9% to Rs 572 crore for the quarter. Recorded robust growths in specialty therapies like Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology therapies and performed relatively better than the market in acute therapies. Excess heat waves in Q1FY25 lead to unnatural market disturbances in affected geographies. Animal Health business grew 23% for the quarter with basket of strong brands driving outperformance. New launches continue to do well along with promising future launches across key segments. US Generics grew 18% to Rs 461 crore for the quarter. 2 Launches in the US market during the quarter. Ex-US International Formulations grew 2% to Rs 271 crore for the quarter. 206 Cumulative ANDA approvals. API business at Rs 259 crore for the quarter. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth. The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18% during the quarter" Result PDF